These Superhumans Are Real And Their DNA Could Be Worth Billions

Drug companies are exploiting rare mutations that make one person nearly immune to pain, another to broken bones.

What's good for patients is also good for business. The painkiller market alone is worth $18 billion a year. The industry is pressing ahead with research into genetic irregularities. The U.S. Food and Drug Administration is expected to approve a cholesterol-lowering treatment on July 24 from Sanofi and Regeneron Pharmaceuticals based on the rare gene mutation of an aerobics instructor with astoundingly low cholesterol levels. Amgen has a similar cholesterol drug, based on the same discovery, and expects U.S. approval in August. The drugs can lower cholesterol when statins alone don't work. They are expected to cost up to $12,000 per patient per year and bring in more than $1 billion annually.

Read the entire article at Bloomberg

Avi Roy

Oxford

- PhD student researching Aging, Mitochondria, and Regenerative Medicine - I currently write for The Conversation (http://bit.ly/13WVyUW) and I have written for The Guardian (http://bit.ly/13WVtRh) - Ringleader of the Oxford University Scientific Society - Co-conspirator at the Oxford Transhumanism and Emerging Technologies - Designing exciting events with the British Science Association Oxford - Advisory Board member at Lifeboat Foundation's Life Extension Board, and the Sustainability Board - Also, I am an Ultimate (frisbee) enthusiast - Yes, unfortunately that's me trying to catch the frisbee